According to ResearchAndMarkets.com’s new report, “Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report by Therapy Type, by Scale (R&D, Commercial), by Mode, by Workflow (Vector Production, Cell Banking), by Region, and Segment Forecasts, 2021 – 2028“, the global cell and gene therapy manufacturing market size is expected to reach $57.4 billion by 2028.
 
The market is estimated to grow at a CAGR of 20.3% from 2021 to 2028 due to an exponential rise in clinical pipeline along with a rising number of regulatory approvals for advanced therapies.
 
With this growth are promising opportunities for contract development of cell and gene therapies. Sponsors are forming strategic alliances with contract manufacturers to help accelerate R&D of their candidate programs, increasing demand for CMOs/CDMOs services.
 
Several new methods are being introduced to help advance cell and gene therapy manufacturing, including the potential of single-use technology in production workflows. This method is increasingly gaining attention to help speed the development process while reducing the overall cost and production timeline. Such technological advancements are expected to further drive market growth over the next few years.